Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Orlaith EI Panel

Scaling Your Business Panel Participation

April 22nd 2024

Read More

InterTrade

InterTrade Ireland All Island Venture Capital Conference

April 22nd 2024

Read More

Banner

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers

April 8th 2024April 8th 2024

Read More

Shorla Oncology

We are delighted to be attending the HOPA 2024 conference at Tampa Florida from 3-6 April. We are looking forward to meeting you at Booth #620.

March 26th 2024March 26th 2024

Read More

Shorla Oncology

Shorla Oncology Achieves Great Place to Work Certification

March 26th 2024

Read More

Photo

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for novel formulation to treat breast and ovarian cancer

January 9th 2024

Read More

Banner

Shorla Oncology attending JP Morgan Healthcare Conference

December 8th 2023

Read More

Rayna

Press Release: Shorla Oncology Welcomes Rayna Sethi Herman as Chief Commercial Officer

December 8th 2023

Read More

Banner

Shorla Oncology at ASH Annual Meeting and Exposition

November 21st 2023

Read More

Older posts
Newer posts
Page1 … Page3 Page4 Page5 … Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.